10-Q: TriSalus Life Sciences Reports Third Quarter 2024 Financial Results, Revenue Growth Continues

TriSalus Life Sciences reports a 41.5% increase in revenue for the third quarter of 2024 compared to the same period in 2023, driven by increased sales of its TriNav infusion system.

Summary

• TriSalus Life Sciences reported a net loss of $2.4 million for the three months ended September 30, 2024, compared to a net loss of $1.4 million for the same period in 2023.
• Revenue for the third quarter of 2024 increased by 41.5% to $7.3 million, up from $5.2 million in the third quarter of 2023, primarily due to increased sales of the TriNav infusion system.
• The company's gross profit for the third quarter of 2024 was $6.3 million, compared to $4.6 million in the third quarter of 2023.
• Research and development expenses decreased by 55.6% to $4.2 million in the third quarter of 2024, compared to $9.5 million in the third quarter of 2023.
• Sales and marketing expenses increased by 30.9% to $6.1 million in the third quarter of 2024, compared to $4.7 million in the third quarter of 2023.
• General and administrative expenses decreased by 47.6% to $4.7 million in the third quarter of 2024, compared to $9.0 million in the third quarter of 2023.
• The company's net loss per common share was $0.12 for the third quarter of 2024, compared to $0.14 for the same period in 2023.
• For the nine months ended September 30, 2024, the company reported a net loss of $19.9 million, compared to a net loss of $23.7 million for the same period in 2023.
• Revenue for the nine months ended September 30, 2024, increased by 65.5% to $21.2 million, up from $12.8 million in the same period in 2023.
• The company's gross profit for the nine months ended September 30, 2024, was $18.3 million, compared to $10.8 million in the same period in 2023.
• Research and development expenses decreased by 33.3% to $14.7 million for the nine months ended September 30, 2024, compared to $22.1 million for the same period in 2023.
• Sales and marketing expenses increased by 64.7% to $18.8 million for the nine months ended September 30, 2024, compared to $11.4 million for the same period in 2023.
• General and administrative expenses decreased by 23.9% to $13.3 million for the nine months ended September 30, 2024, compared to $17.5 million for the same period in 2023.
• The company's net loss per common share was $0.91 for the nine months ended September 30, 2024, compared to $5.72 for the same period in 2023.
• The company has a history of recurring operating losses and an accumulated deficit of $269.4 million as of September 30, 2024.
• The company expects that its existing cash and cash equivalents will not be sufficient to fund its projected liquidity requirements for the next 12 months from the issuance date of the financial statements.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue growth is strong, the company continues to incur losses and faces significant financial challenges. The need for additional capital and the presence of material weaknesses in internal controls are concerning, but the company is taking steps to address these issues. The sentiment is neutral to slightly negative.

Positives

• The company experienced significant revenue growth, with a 41.5% increase in the third quarter and a 65.5% increase for the nine months ended September 30, 2024.
• Gross profit also saw substantial growth, increasing by 37.8% in the third quarter and 69.8% for the nine months ended September 30, 2024.
• Research and development expenses decreased significantly, by 55.6% in the third quarter and 33.3% for the nine months ended September 30, 2024.
• The company raised $12.4 million from the sale of common stock under the SEPA during the nine months ended September 30, 2024.
• The company entered into a credit agreement with OrbiMed, providing up to $50 million in senior secured term debt, of which $25 million was drawn initially.

Negatives

• The company continues to incur net losses, with a net loss of $2.4 million for the third quarter of 2024 and $19.9 million for the nine months ended September 30, 2024.
• The company's operating expenses remain high, with sales and marketing expenses increasing by 30.9% in the third quarter and 64.7% for the nine months ended September 30, 2024.
• The company has an accumulated deficit of $269.4 million as of September 30, 2024.
• The company expects that its existing cash and cash equivalents will not be sufficient to fund its projected liquidity requirements for the next 12 months.

Risks

• The company has a limited operating history and has incurred significant losses since its inception.
• The company's ability to generate revenue is primarily dependent on the sales of its TriNav device.
• The company is early in its pharmaceutical development efforts for nelitolimod and may not be able to obtain regulatory approval or commercialize it successfully.
• The company may not be able to generate sufficient cash to service its indebtedness or borrow additional funds pursuant to its Loan Facility.
• The company is subject to numerous complex regulatory requirements, and failure to comply with these regulations may harm its business.
• The company's management has identified material weaknesses in its internal control over financial reporting.
• The price of the company's securities has been and may continue to be volatile.

Future Outlook

The company expects that its existing cash and cash equivalents will not be sufficient to fund its projected liquidity requirements for the next 12 months from the issuance date of the financial statements. If the company is able to achieve certain targets specified in the Credit Agreement and draw the remainder of the funds available, and if market conditions allow the company to sell additional shares under the SEPA, the company believes it can fund its operations through the end of 2025.

Industry Context

The company operates in the competitive biopharmaceutical and medical device industries, facing competition from major multinational companies, established biotechnology companies, and research institutions. The company's focus on innovative drug delivery technology and immuno-oncology therapeutics positions it within a rapidly evolving market.

Comparison to Industry Standards

• The company's revenue growth of 41.5% in the third quarter and 65.5% for the nine months ended September 30, 2024, indicates strong market demand for its TriNav infusion system, which is a positive sign compared to industry averages.
• The company's gross margin of 86.3% in the third quarter of 2024 is relatively high, suggesting a strong pricing strategy and efficient cost management compared to industry benchmarks.
• The company's significant decrease in research and development expenses, by 55.6% in the third quarter and 33.3% for the nine months ended September 30, 2024, may indicate a shift in focus towards commercialization and away from early-stage research, which is a common trend for companies in the later stages of development.
• The company's increase in sales and marketing expenses, by 30.9% in the third quarter and 64.7% for the nine months ended September 30, 2024, reflects its efforts to expand its market reach and increase adoption of its products, which is a typical strategy for companies in the commercialization phase.
• The company's net loss per share of $0.12 for the third quarter of 2024 and $0.91 for the nine months ended September 30, 2024, is consistent with the financial performance of other early-stage biotechnology and medical device companies that are still in the process of commercializing their products and developing new product candidates.
• The company's reliance on third-party manufacturers and suppliers is a common practice in the industry, but it also exposes the company to supply chain risks and potential disruptions, which is a concern for many companies in the sector.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the company's financial performance and the need for additional capital.
• Employees may be affected by potential cost-cutting measures or changes in the company's strategic direction.
• Customers may benefit from the company's innovative products, but may also be affected by potential supply chain disruptions.
• Suppliers may be affected by changes in the company's manufacturing and supply chain strategies.
• Creditors may be affected by the company's ability to service its debt obligations.

Next Steps

• The company will continue to focus on the commercialization of TriNav and the development of nelitolimod.
• The company will continue to enroll patients in its PERIO-3 clinical trial for pancreatic cancer.
• The company will continue to evaluate potential partners to advance the uveal melanoma indication.
• The company will continue to monitor the effectiveness of its remediation plan for material weaknesses in internal control over financial reporting.
• The company will continue to explore options for raising additional capital.

Key Dates

Keywords

TriNav, nelitolimod, Pressure Enabled Drug Delivery, PEDD, liver cancer, pancreatic cancer, drug delivery, immuno-oncology, clinical trials, medical device, pharmaceutical, revenue, financial results, warrants, debt, OrbiMed, SEPA